COSMIN database

Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy

Gewandter, J. S., Burke, L., Cavaletti, G., Dworkin, R. H., Gibbons, C., Gover, T. D., Herrmann, D. N., McArthur, J. C., McDermott, M. P., Rappaport, B. A., Reeve, B. B., Russell, J. W., Smith, A. G., Smith, S. M., Turk, D. C., Vinik, A. I., and Freeman, R.
INTRODUCTION: No treatments for axonal peripheral neuropathy are approved by the United States Food and Drug Administration (FDA). Although patient- and clinician-reported outcomes are central to evaluating neuropathy symptoms, they can be difficult to assess accurately. The inability to identify efficacious treatments for peripheral neuropathies could be due to invalid or inadequate outcome measures.

METHODS: This systematic review examined the content validity of symptom-based measures of diabetic peripheral neuropathy, HIV neuropathy, and chemotherapy-induced peripheral neuropathy.

RESULTS: Use of all FDA-recommended methods to establish content validity was only reported for 2 of 18 measures. Multiple sensory and motor symptoms were included in measures for all 3 conditions; these included numbness, tingling, pain, allodynia, difficulty walking, and cramping. Autonomic symptoms were less frequently included.

CONCLUSIONS: Given significant overlap in symptoms between neuropathy etiologies, a measure with content validity for multiple neuropathies with supplemental disease-specific modules could be of great value in the development of disease-modifying treatments for peripheral neuropathies. Muscle Nerve 55: 366-372, 2017.
Muscle Nerve
Publication year:
Biological and physiological variables:
Biological and physiological variables
Symptom status:
Physical state
Functional status:
Physical functioning
Role functioning
Social functioning
Adults (18-65)
Seniors (65+)
Certain infections and parasitic diseases and related symptoms
Diseases of and symptoms related to the nervous system
Endocrine, nutritional and metabolic diseases and related symptoms
Neoplasms and related symptoms
PRO / non-PRO:
Patient Reported Outcome
Type of measurement instrument:
1 - Questionnaires
2 - Interviews
BPNS - Brief Peripheral Neuropathy Screen
CIPN - Chemotherapy-induced Peripheral Neuropathy Assessment Tool [alias: CIPNAT]
CIPN-R-ODS - Chemotherapy-induced peripheral neuropathy Rasch-built Overall Disability Scale
EORTC QLQ-CIPN20 - European Organization of Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy   
FACT/GOG-Ntx - Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity
FACT/GOG-Taxane - Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Taxane   
MNSI - Michigan Neuropathy Screening instrument   
mTCNS - Modified Toronto Clinical Neuropathy Scale
NCI-CTC - National Cancer Institute - Common Toxicity Criteria
NeuroQoL - Neuropathy - and Foot Ulcer-Specific Quality of Life Measurement
Norfolk QOL-DN - Norfolk Quality of Life Questionnaire - Diabetic Neuropathy   
NSS - Neuropathy Symptom Score
NTSS-6 - Neuropathy Total Symptom Score-6
O-ANQ - Oxaliplatin-Associated Neuropathy Questionnaire
PNQ - Patient Neurotoxicity Questionnaire
PNS - Peripheral Neuropathy Scale
SCIN - Scale for Chemotherapy-Induced Long Term Neurotoxicity
SPNSQ - Subjective Peripheral Neuropathy Screen Questionnaire
TCNS - Toronto Clinical Neuropathy Score
TNS - Total Neuropathy Score